Stereotactic arrhythmia radioablation: radiobiology, clinical evidence, and emerging applications
- 1Department of Radiation Oncology, Weill Cornell Medicine, NewYork Presbyterian Hospital
- 2Division of Cardiology, Weill Cornell Medicine, NewYork Presbyterian Hospital
- 3Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine
Abstract
STereotactic Arrhythmia Radioablation (STAR) has emerged as a promising non-invasive treatment for patients with refractory cardiac arrhythmias who are unsuitable for or have failed conventional catheter ablation. Initially developed for ventricular tachycardia (VT), STAR has demonstrated encouraging efficacy in reducing arrhythmia burden while avoiding the risks associated with invasive procedures. More recently, limited and early clinical experience has explored the potential application of STAR in paroxysmal atrial fibrillation (AF), including the feasibility of non-invasive pulmonary vein isolation; however, clinical evidence in AF remains anecdotal and investigational. Despite these advances, the biological mechanisms underlying STAR remain incompletely understood. While early hypotheses attributed its therapeutic effects primarily to radiation-induced fibrosis, accumulating evidence suggests that rapid anti-arrhythmic effects are mediated by early electrophysiological reprogramming and conduction remodeling, whereas delayed vascular injury, inflammation, and fibrosis may contribute to durable substrate modification and long-term toxicity. This evolving paradigm has important implications for optimizing radiation dose, fractionation strategies, and minimizing cardiac toxicity. Advances in imaging, electroanatomical mapping, and treatment planning are further improving treatment precision. Ongoing prospective clinical trials and international collaborative initiatives are expected to provide robust evidence regarding efficacy, safety, and long-term outcomes. This review summarizes current knowledge on the radiobiological mechanisms, clinical applications, and future perspectives of STAR, highlighting the key challenges for its integration into contemporary cardiac electrophysiology, as well as describing our current clinical trial investigating the role of dose and fractionation for this technique.
Related
- Neoadjuvant Stereotactic Ablative Radiotherapy Before Inferior Vena Cava Thrombectomy for Renal Cell Carcinoma : A Phase 2 Nonrandomized Clinical Trial
- Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
- Cardiac Stereotactic Body Radiotherapy for Refractory Ventricular Tachycardia — Target Definition, Dose Distribution, and Clinical Trajectory —
- Stereotactic Radiosurgery for an Unresectable Jugulotympanic Paraganglioma: Clinical Response and Acute Toxicity in a 70-Year-Old Patient.
- A hybrid quantum algorithm for multi-resolution arrhythmia classification
BibTeX
@article{gregucci2026stereotactic,
title = {{Stereotactic arrhythmia radioablation: radiobiology, clinical evidence, and emerging applications}},
author = {Fabiana Gregucci and John Ng and Jim W. Cheung and George Thomas and Christopher F. Liu and Steven M. Markowitz and Fereshteh Talebi and Brendan Roth and Maahi Patel and Ashley Teal and Leland Muller and Xi Kathy Zhou and Ryan Pennell and Silvia C. Formenti},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1953364},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1953364/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Stereotactic arrhythmia radioablation: radiobiology, clinical evidence, and emerging applications
AU - Fabiana Gregucci
AU - John Ng
AU - Jim W. Cheung
AU - George Thomas
AU - Christopher F. Liu
AU - Steven M. Markowitz
AU - Fereshteh Talebi
AU - Brendan Roth
AU - Maahi Patel
AU - Ashley Teal
AU - Leland Muller
AU - Xi Kathy Zhou
AU - Ryan Pennell
AU - Silvia C. Formenti
PY - 2026
DA - 2026/10/26
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1953364
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1953364/full
AB - STereotactic Arrhythmia Radioablation (STAR) has emerged as a promising non-invasive treatment for patients with refractory cardiac arrhythmias who are unsuitable for or have failed conventional catheter ablation. Initially developed for ventricular tachycardia (VT), STAR has demonstrated encouraging efficacy in reducing arrhythmia burden while avoiding the risks associated with invasive procedures. More recently, limited and early clinical experience has explored the potential application of STAR in paroxysmal atrial fibrillation (AF), including the feasibility of non-invasive pulmonary vein isolation; however, clinical evidence in AF remains anecdotal and investigational. Despite these advances, the biological mechanisms underlying STAR remain incompletely understood. While early hypotheses attributed its therapeutic effects primarily to radiation-induced fibrosis, accumulating evidence suggests that rapid anti-arrhythmic effects are mediated by early electrophysiological reprogramming and conduction remodeling, whereas delayed vascular injury, inflammation, and fibrosis may contribute to durable substrate modification and long-term toxicity. This evolving paradigm has important implications for optimizing radiation dose, fractionation strategies, and minimizing cardiac toxicity. Advances in imaging, electroanatomical mapping, and treatment planning are further improving treatment precision. Ongoing prospective clinical trials and international collaborative initiatives are expected to provide robust evidence regarding efficacy, safety, and long-term outcomes. This review summarizes current knowledge on the radiobiological mechanisms, clinical applications, and future perspectives of STAR, highlighting the key challenges for its integration into contemporary cardiac electrophysiology, as well as describing our current clinical trial investigating the role of dose and fractionation for this technique.
SN - 2234-943X
ER -